Category: News

Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy and radiation. Each poses their own benefits, risks and limitations. Together with better diagnosis, these three pillars have been refined over many decades to the point where some cancers are not necessarily considered “the death sentence it used to be”. However, there were still almost 10 million deaths worldwide attributable to cancer in 2020 – and over 18 million cases diagnosed globally that year.

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In October, Merchant Funds’ Andrew Chapman selected Dimerix as one of his favourite stocks, highlighting the company as being, at the time,…

After making a major greenfield discovery at their flagship Woyla project, Far East Gold (ASX: FEG) finished up the second quarter of FY23 with a plan to launch into a resource definition drilling campaign that will hopefully provide a tangible glimpse of the significant gold-silver resource potential that FEG has confirmed Woyla possesses.

If 2022 was the year in which Propell (ASX: PHL) launched itself on the pathway to profitability, 2023 might be when it gets to significantly pick up speed, according to the company’s recently announced Q2 FY23 quarterly activities report.

In the lead up to this week’s The Insider: Meet the Fund Manager, Graeme Carson from Cyan Investment Management sat down with Reach Markets to provide a bit of information about his investment strategy, industries of interest and view on the market.

Some call it the ‘least bad option’, some a ‘dumb idea that won’t go away’. But perhaps it was beloved fictional character Homer J. Simpson who summed it up perfectly when he said, “Ooo a trillion dollar bill, that’s a spicy meatball!”

COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by the World Health Organisation, but in the same year nearly 10 million lives were lost to a much deadlier adversary – cancer. Fighting back is clinical-stage biotech company Prescient Therapeutics (ASX: PTX).

Just a day away from another Fed rate hike decision, US markets have surged after fourth quarter inflation data showed labour costs had increased at their slowest pace in a year. The S&P 500 stacked on almost 1.5%, the Nasdaq over 1.6%. Data released yesterday showed demand for US crude and petroleum products also rose in November, which combined with a slightly weakened US dollar allowed Brent oil to finish up 1% last night.

The largest solar power project in Australia’s history has hit a brick wall, with two of Australia’s richest billionaires now battling it out in a high profile rivalry that is forming the debate on what is the most viable form of renewable energy.

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In July, Horizon 3 Healthcare’s Matt McNamara selected EBR Systems as one of his favourite stocks, pointing to the company’s patented wireless…

meldCX’s AI testing results produced 99.25% accuracy, which is in excess of their target accuracy baseline with the client and is set to help the largest poultry producer in the US reduce waste, assist with employee overheads and help ease the restraints of staffing shortages. This is another example of why meldCX’s AI platform is being adopted by some of the largest companies in the world.

The ASX 200 is now less than 2% away from it’s all time high, after stacking on around 7% January gains in a strong start to the year. Traders will be eagerly watching fourth quarter CPI data that gets released today at 11:30am (AEDT), with the RBA forecasting 6.5%. The VIX continues to hover around 19-20 while all US index’s ended the day only marginally different Monday.